Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Inhibikase Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$1.67

+0.05 (+2.93%)

D 38Pipeline Score Fair Value Biotech · Clinical
Market Cap
223.14 M
EPS
-0.43
P/E Ratio
-
Value Trade
1.43 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    -

  • R&D Expenses

    10.84 M

  • Operating CF

    -12.06 M

  • Total Assets

    173.33 M

  • Total Liabilities

    5.71 M

  • Equity

    167.62 M

  • D/E Ratio

    12,345

-8.15 %
Week
-0.59 %
1 Month
-2.87 %
3 Month
7.64 %
6 Month
-93.86 %
5 Year
-97.36 %
All Time
Cash Data
Healthy

  • Cash Position

    170.37 M

  • Monthly Burn

    4.02 M

  • Runway

    41.4 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
424.71 K
52 Week Range
1.33 - 2.26
% held by Insiders
24.61 %
% held by Institutions
69.14 %
Enterprise Value
52.77 M
Total Shares
75.18 M
Short %
18.6 %
Float Shares
41.95 M
Company Description
HQ: 1000 N. WEST STREET, SUITE 120...
Employees:35
https://www.inhibikase.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D38
Pipeline Score
$227M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
1.0x
rNPV / MCap
Top 48%
Micro Cap
(rank 472 of 905)
Percentile Rank
Inhibikase Therapeutics, Inc. faces pipeline headwinds (38/100), with $909M risk-adjusted pipeline value, led by IKT-001 in Pulmonary Arterial Hypertension (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IKT-001
Small molecule		Pulmonary Arterial HypertensionPhase 3NCT0736533248% $836M RECRUITING 486 VERY_FAST B (69) Dec 1, 2029MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
IKT-001
Pulmonary Arterial Hypertension
Phase 2b
2025-08-15
IKT-001
Pulmonary Arterial Hypertension
Phase 2b
2025-08-15
IKT-001
Pulmonary Arterial Hypertension
Phase 2b
2025-08-15
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IKT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IKT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IKT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IKT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IKT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IKT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Inhibikase Therapeutics, Inc. (IKT) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IKT ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Pulmonary Arterial Hypertension #8 of 13 PHASE 3 IKT-001
MRK UTHR INSM
$8.48B 0.92 CONTENDER